<table>
<thead>
<tr>
<th>Country</th>
<th>Regulatory Authority (RA)</th>
<th>Link to the RA and contact point</th>
<th>Listed product stream(s)</th>
<th>Listed function(s)*</th>
<th>Date of first listing</th>
<th>Date of renewal</th>
<th>Link to the listing summary</th>
</tr>
</thead>
</table>
| Republic of Korea  | Ministry of Food and Drug Safety (MFDS)       | ▪ Please click [HERE](#) to access the website of the regulatory authority  
▪ Contact point: [intlpharm@korea.kr](mailto:intlpharm@korea.kr) | Medicine(s) (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products) | 1. Vigilance  
2. Licensing establishments  
3. Regulatory inspection (GMP and GSDP)  
4. Laboratory testing  
5. Clinical trials oversight | 26 October 2023 | 5 years from date of initial listing | TBC |
| Republic of Korea  | Ministry of Food and Drug Safety (MFDS)       | ▪ Please click [HERE](#) to access the website of the regulatory authority  
▪ Contact point: [intlpharm@korea.kr](mailto:intlpharm@korea.kr) | Vaccines | 1. Registration and marketing authorization  
2. Vigilance  
3. Market surveillance and control  
4. Licensing establishments  
5. Regulatory inspection (GMP and GSDP)  
6. Laboratory testing  
7. Clinical trials oversight  
8. NRA lot Release | 26 October 2023 | 5 years from date of initial listing | TBC |
| Singapore          | Health Sciences Authority (HSA)               | ▪ Please click [HERE](#) to access the website of the regulatory authority  
▪ Contact point: [hsa_intl_office@hsa.gov.sg](mailto:hsa_intl_office@hsa.gov.sg) | Medicine(s) (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products) | 1. Registration and marketing authorization  
2. Vigilance  
3. Licensing establishments  
4. Regulatory inspection (GMP, GSDP and GCP)  
5. Laboratory testing  
6. Clinical trials oversight | 26 October 2023 | 5 years from date of initial listing | TBC |
| Switzerland        | Swissmedic                                    | ▪ Please click [HERE](#) to access the website of the regulatory authority  
▪ Contact point: [Networking@swissmedic.ch](mailto:Networking@swissmedic.ch) | Medicine(s) (including multisource [generics], and new medicines [new chemical entities], biotherapeutics and similar biotherapeutic products) | 1. Registration and marketing authorization  
2. Vigilance  
3. Market surveillance and control  
4. Licensing establishments | 26 October 2023 | 5 years from date of initial listing | TBC |
| Switzerland | Swissmedic | Vaccines |...
|-------------|------------|----------|
| | ▪ Please click HERE to access the website of the regulatory authority  
▪ Contact point: Networking@swissmedic.ch | 1. Registration and marketing authorization  
2. Vigilance  
3. Market surveillance and control  
4. Licensing establishments  
5. Regulatory inspection (GMP, GSDP and GCP)  
6. Laboratory testing  
7. Clinical trials oversight  
8. NRA lot release | 26 October 2023  
5 years from date of initial listing  
TBC |

* Evaluation of the regulatory system is always performed in conjunction with the function(s) for which listing is sought